BioCentury
ARTICLE | Clinical News

Sonidegib: Additional Phase II data

June 2, 2014 7:00 AM UTC

On secondary endpoints, low-dose sonidegib led to a disease control rate (DCR) of 90.9% in patients with locally advanced BCC and 92.3% in patients with metastatic BCC. High-dose sonidegib led to a DC...